Redhill Biopharma Ltd.

(RDHL) Trade

By |

Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Contact Information

Website: www.redhillbio.com
Email: investors@redhillbio.com
Main Phone: +972 35413131
Address: 21 Ha'arba'a Street
City / Town: Tel Aviv
Country: ISR
Postal Code: 6473921

Issuer Information

Exchange: NSD
CEO: Dror Ben-Asher
Employees: 155
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Contact Information

Website: www.redhillbio.com
Email: investors@redhillbio.com
Main Phone: +972 35413131
Address: 21 Ha'arba'a Street
City / Town: Tel Aviv
Country: ISR
Postal Code: 6473921

Issuer Information

Exchange: NSD
CEO: Dror Ben-Asher
Employees: 155
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 6.86 $ -0.11 (-1.58%)
Last Price 6.86 Change $ -0.11 Change % -1.58 Tick N/A
Bid 6.76 Bid Size 2,000.00 Ask 7.15 Ask Size 100.00
Open 7.00 High 7.01 Low 6.80 Prev Close 6.97
Last Trade Volume 137,369 52 Wk Hi 9.12 52 Wk Low 3.27
Market Cap 241.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 35,269,566.00 EPS (TTM) -1.50 PE Ratio N/A Exchange NSD
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 36 36 36 36
Low Target Price Estimate 17 17 17 17
Mean Target Price Estimate 24 24 24 24
Standard Deviation 10.44 10.44 10.44 10.44
Date of Most Recent Estimate 05/14/18 05/14/18 05/14/18 05/14/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1